Skip to main content
. 2021 Jun 30;18(2):1940650. doi: 10.1080/21645515.2021.1940650

Figure 2.

Figure 2.

Environmental and product factors that contribute to the quality and performance of inhaled monoclonal antibodies that are uses to assure efficacy and safety outcomes.